AV-105 is a florbetapir (18F)-radiolabeled slyrylpyridine sulfonate precursor extracted from patent WO2010078370A1, Example 1.5[1]. AV-105 is capable of synthesizing 18F-radiolabeled compounds that can be used for positron emission tomography (PET) imaging of brain neurodegenerative diseases[2, 3].
References:
[1] Benedum T, Golding G, Lim N, et al. Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof[P]. 2010-7-8.
[2] Li C, Zhang P, Nie R, et al. Targeting amyloids with [18F] AV-45 for medullary thyroid carcinoma positron emission tomography/computed tomography imaging: a pilot clinical study[J]. Molecular Pharmaceutics, 2022, 19(2): 584-591.
[3] Xie Q, Xie J K, Ni M. 18 Automatic synthesis of F-AV-45 and its clinical application in Alzheimer's disease[J]. Hellenic Journal of Nuclear Medicine, 2023.
AV-105是一种Florbetapir (18F)-放射性标记的slyrylpyridine磺酸酯前体，该前体从专利WO2010078370A1，示例1.5提取[1]。AV-105能够合成18F-放射性标记的化合物，可用于大脑神经退行性疾病的正电子发射断层扫描（PET）成像[2, 3]。